Biocept says more than 250,000 coronavirus (COVID-19) testing samples received to date for processing at its laboratory

Biocept, Inc. (NASDAQ:BIOC) has provided an update on its coronavirus (COVID-19) testing with more than 250,000 samples received to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory.

“We continue to serve our community during the pandemic with this important testing and have received nearly 55,000 COVID-19 samples since the beginning of 2021,” said Michael Nall, president and CEO of Biocept in a statement.

“I’m proud of our team’s ability to process these tests quickly. Even with the increasing volume of COVID-19 samples received by our lab, the vast majority of test results to date have been sent to our health providers within 48 hours. As previously noted, we expect COVID-19 RT-PCR testing will be a significant component of our business until the pandemic subsides.”

READ: Biocept enters into laboratory services agreements with independent physician associations for full array of its Target Selector liquid biopsy oncology assays

Biocept is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer.

The company’s patented Target Selector liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient’s disease and therapeutic options.

Additionally, Biocept is offering nationwide COVID-19 polymerase chain reaction (PCR) testing to support public health efforts during this unprecedented pandemic.

At the end of December 2020, Biocept revealed that it had entered into laboratory services agreements with independent physician associations (IPAs) providing physicians and patients in-network access to the company’s full array of Target Selector liquid biopsy oncology assays and services.

The group said both IPAs are headquartered in San Diego and combined, serve more than 70,000 covered lives in the Southern California region.  

Contact the author at [email protected]

Story by ProactiveInvestors